摘要
目的 探讨凋亡抑制基因bcl 2、bcl xl在上皮性卵巢肿瘤中的表达及其相互关系。方法 应用免疫组织化学S P方法检测 10例正常卵巢、2l例良性上皮性卵巢肿瘤、12例交界性肿瘤、72例恶性肿瘤组织中bcl 2、bcl xl基因表达情况 ,并分析其表达与不同临床病理特征之间的关系。结果 bcl 2在正常卵巢、良性上皮性卵巢肿瘤、交界性肿瘤、恶性肿瘤中阳性表达率分别为 10 % (1/ 10 )、19.1% (4 / 2 1)、5 0 % (6 / 12 )、和 5 5 .6 % (4 1/ 72 ) ,bcl xl在正常卵巢、良性上皮性卵巢肿瘤中均为阴性表达 ,在交界性肿瘤和恶性肿瘤中阳性表达率分别为 16 .6 7%和 4 8.6 1%。bcl 2与肿瘤的分化程度有关 ,分化差者bcl 2表达低。bcl xl与肿瘤的临床分期有关 ,在Ⅲ、Ⅳ期恶性肿瘤中的阳性率分别为 5 4 .0 5 %、71.4 3% ,Ⅰ、Ⅱ期为 12 .5 0 %、4 5 .0 0 % ;两者均与肿瘤的病理学类型无关。未发现两者有相关关系。结论 本实验结果表明bcl 2和bcl x1基因参与了卵巢肿瘤的发生发展过程 ,可作为卵巢恶性肿瘤的分子生物学指标之一。
Objective To investigate the expression of bcl-2 and bcl-xl and their significance in epithelial ovarian neoplasm. Methods bcl-2 and bcl-xl were detected by immunohistochemical SP technique in 72 cases of ovarian cancer,12 cases of bordline tumor,2l cases of benign tumor and l0 cases of normal ovary.The relationship between bcl-2 and bcl-xl proteins and aspects of ovarian cancer was analyzed.Results Positive expression rates of bcl-2 was 10%(1 /10)、19.1%(4 /21)、50%(7 /12)、and 55.6%(41 /72) in normal ovary, benign tumor, bordline tumor,and in epithelial ovarian cancer respectively.Expression of bcl-xl gene was negative in normal ovary and benign tumor and its positive rate was 16.67% and 48.61% in bordline tumor and in epithelial ovarian cancer respectively.In epithelial ovarian cancer,the presence of bcl-2 protein was not related to histological types and clinical stages but related to cell differentiation.The positive rate of bcl-xl protein in stage Ⅰ、Ⅱ、Ⅲ、Ⅳ was 12.50%、 45.00%、54.05%、71.43% respectively(P<0.05).and it was related with clinical stages. There was no correlation between the expression of the two proteins.Conclusion The results suggest that bcl-2 and bcl-xl gene may be used as a valuable biomarker of epithelial ovarian carcinoma.
出处
《肿瘤》
CAS
CSCD
北大核心
2003年第5期406-408,共3页
Tumor
